Trials / Not Yet Recruiting
Not Yet RecruitingNCT06662773
Drug-Drug Interaction (DDI) Study for TQB3616
Phase I Clinical Trial Evaluating Drug Drug Interactions of TQB3616 Capsules
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the effect of itraconazole/rifampicin on the pharmacokinetics of TQB3616 capsules. To assess the safety of a single dose of oral TQB3616 capsules and in combination with itraconazole/rifampicin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3616 capsule + itraconazole | C2/4/6 inhibitors + CYP3A metabolic enzyme inhibitors |
| DRUG | TQB3616 capsule + rifampicin | C2/4/6 inhibitors + Non-specific cytochrome P450 enzyme inducer |
Timeline
- Start date
- 2024-11-01
- Primary completion
- 2025-03-01
- Completion
- 2025-07-01
- First posted
- 2024-10-29
- Last updated
- 2024-10-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06662773. Inclusion in this directory is not an endorsement.